Saxenda Thailand

The first GLP-1 ever approved for weight management

Saxenda's clinical story starts seven years before Wegovy and almost a decade before Mounjaro. When the US FDA approved liraglutide 3 mg for chronic weight management in December 2014, it created the entire regulatory pathway that every subsequent GLP-1 weight-loss drug has used.

Liraglutide had first been approved as Victoza in 2010, at doses up to 1.8 mg daily, for the treatment of type-2 diabetes. The Novo Nordisk team observed consistent weight loss as a secondary endpoint and tested whether escalating to 3 mg daily would produce clinically meaningful weight management in non-diabetic patients.

That trial produced the regulatory template. Wegovy's 2021 approval, Zepbound's 2023 approval, and any future weight-management GLP-1 approval all rely on the same framework that the FDA built around the SCALE program — adult population, BMI thresholds, 5% and 10% weight-loss responder definitions, comorbidity sub-analyses.

In other words: every modern GLP-1 weight-loss drug stands on Saxenda's regulatory shoulders, even when the marketing language treats it as obsolete.

The daily-injection trade-off

Saxenda is injected every day. Mounjaro, Wegovy and Ozempic are injected every week. That single specification produces a different shape of drug-exposure curve, a different shape of side-effect profile, and a different shape of patient relationship with the molecule.

The honest summary. Saxenda is best suited to patients who deliberately want the higher-frequency-but-lower-exposure profile. That is a real clinical population — but it is not the default. Most patients will be better served by a weekly agent.

Daily dosing and lean-mass preservation

An under-discussed signal in body-composition sub-analyses: liraglutide's daily-dosing pattern may preserve more lean mass during weight loss than once-weekly agents do. The hypothesis is mechanistic, the data is suggestive rather than conclusive, and it matters for any patient prioritising body recomposition rather than scale-weight alone.

The mechanistic argument

Weekly GLP-1 agents like semaglutide produce a sawtooth exposure curve: a peak in the first few days after injection, then a tapering trough across the rest of the week. Daily liraglutide, with its 13-hour half-life, produces a much flatter steady-state — smaller daily fluctuations in plasma drug concentration and, downstream, in glucose-insulin signalling.

The hypothesis: smaller daily insulin-glucose oscillations create a more anabolic environment for skeletal muscle than larger weekly oscillations do. The SCALE Insulin substudy and related body-composition sub-analyses reported lean-mass preservation that was numerically favourable on liraglutide, though absolute differences were modest.

For body-recomposition-focused patients — bodybuilders, athletes mid-cut, anyone for whom DEXA scan output matters more than scale weight — this is a clinical conversation worth having before defaulting to a weekly agent.

Why some Thai endocrinologists start with Saxenda

Saxenda is not always the destination — but it is often the smartest first step. The shorter half-life, the lower per-shot price, and the gentler dose ladder make it a sensible 8 to 12 week introduction to GLP-1 therapy before transitioning to a weekly agent if the patient does well.

The transition pattern. A common Thai endocrinology sequence is 8 to 12 weeks on Saxenda titrated to 1.8 mg or 3 mg daily, then a one-week wash-out, then initiation of weekly Mounjaro 2.5 mg or weekly Wegovy 0.25 mg. The Saxenda exposure pre-conditions the gut and gives the doctor a clean read on individual GLP-1 tolerability before committing to the longer-half-life weekly agents.

Doctor-led prescription required. Authentic Novo Nordisk supply only.

See your expected trajectory on Saxenda.

Trajectory based on the SCALE Obesity clinical-trial mean. Your individualized program is confirmed in consultation — this is an evidence-based estimate, not a guarantee.

Three foundations of our weight-loss program.